Coherus BioSciences Q1 2025 10-Q Filed
Ticker: CHRS · Form: 10-Q · Filed: May 12, 2025 · CIK: 1512762
Sentiment: neutral
Topics: 10-Q, financials, expenses
TL;DR
Coherus BioSciences Q1 2025 10-Q shows $37.5M SG&A.
AI Summary
Coherus BioSciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported Selling, General & Administrative Expense of $37.5 million for the first quarter of 2025. The filing also details changes in equity accounts such as Additional Paid-In Capital and Retained Earnings.
Why It Matters
This filing provides investors with an update on Coherus BioSciences' financial performance and operational status for the first quarter of 2025, including key expense figures.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- $37.5M — Selling, General & Administrative Expense (Q1 2025)
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Filer
- March 31, 2025 (date) — Reporting period end date
- $37.5 million (dollar_amount) — Selling, General & Administrative Expense for Q1 2025
FAQ
What was Coherus BioSciences' total revenue for the first quarter of 2025?
The provided excerpt does not contain specific revenue figures for the first quarter of 2025.
What is the company's net income or loss for the period ending March 31, 2025?
The excerpt does not specify the net income or loss for the period ending March 31, 2025.
Were there any significant gains or losses on the sale of interest in projects reported?
The filing mentions 'GainLossOnSaleOfInterestInProjects' with values of $115,614,548 and $115,907,216, indicating such gains or losses were reported.
What were the changes in Additional Paid-In Capital during the first quarter of 2025?
The filing indicates changes in 'us-gaap:AdditionalPaidInCapitalMember' for the period ending March 31, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Coherus BioSciences, Inc. (CHRS).